-
EP4132908
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4132908
| EP4132908 - INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 26.10.2023 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 13.01.2023 | ||
| Former | The international publication has been made Status updated on 09.10.2021 | ||
| Former | unknown Status updated on 24.05.2021 | Most recent event Tooltip | 07.08.2024 | New entry: Decision on request for further processing | Applicant(s) | For all designated states Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210 / US | [2023/07] | Inventor(s) | 01 /
GIROUX, Simon 50 Northern Avenue Boston, Massachusetts 02210 / US | 02 /
CLARK, Michael Philip 50 Northern Avenue Boston, Massachusetts 02210 / US | 03 /
BRODNEY, Michael Aaron 50 Northern Avenue Boston, Massachusetts 02210 / US | 04 /
NUHANT, Philippe Marcel 50 Northern Avenue Boston, Massachusetts 02210 / US | 05 /
ALLEN, Emily Elizabeth 50 Northern Avenue Boston, Massachusetts 02210 / US | 06 /
FIMOGNARI, JR., Robert Francis 50 Northern Avenue Boston, Massachusetts 02210 / US | 07 /
ZAKY, Mariam 50 Northern Avenue Boston, Massachusetts 02210 / US | 08 /
BOYD, Michael John 50 Northern Avenue Boston, Massachusetts 02210 / US | 09 /
DEININGER, David D. 50 Northern Avenue Boston, Massachusetts 02210 / US | 10 /
ZHANG, Hu 50 Northern Avenue Boston, Massachusetts 02210 / US | 11 /
DENG, Hongbo 50 Northern Avenue Boston, Massachusetts 02210 / US | 12 /
COLLIER, Philip Noel 50 Northern Avenue Boston, Massachusetts 02210 / US | 13 /
MAXWELL, Brad 50 Northern Avenue Boston, Massachusetts 02210 / US | 14 /
WAAL, Nathan D. 50 Northern Avenue Boston, Massachusetts 02210 / US | 15 /
RONKIN, Steven M. 50 Northern Avenue Boston, Massachusetts 02210 / US | 16 /
WANG, Jian 50 Northern Avenue Boston, Massachusetts 02210 / US | 17 /
TANG, Qing 50 Northern Avenue Boston, Massachusetts 02210 / US | 18 /
FLEMING, Gabrielle Simone 50 Northern Avenue Boston, Massachusetts 02210 / US | 19 /
JONES, Peter 50 Northern Avenue Boston, Massachusetts 02210 / US | 20 /
BOUCHER, Diane Marie 50 Northern Avenue Boston, Massachusetts 02210 / US | 21 /
FANNING, Lev T.D. 50 Northern Avenue Boston, Massachusetts 02210 / US | 22 /
HALL, Amy B. 50 Northern Avenue Boston, Massachusetts 02210 / US | 23 /
HURLEY, Dennis James 50 Northern Avenue Boston, Massachusetts 02210 / US | 24 /
JOHNSON, JR., Mac Arthur 50 Northern Avenue Boston, Massachusetts 02210 / US | 25 /
MAXWELL, John Patrick 50 Northern Avenue Boston, Massachusetts 02210 / US | 26 /
SWETT, Rebecca Jane 50 Northern Avenue Boston, Massachusetts 02210 / US | 27 /
TAPLEY, Timothy Lewis 50 Northern Avenue Boston, Massachusetts 02210 / US | 28 /
THOMSON, Stephen A. 50 Northern Avenue Boston, Massachusetts 02210 / US | 29 /
DAMAGNEZ, Veronique 50 Northern Avenue Boston, Massachusetts 02210 / US | 30 /
COTTRELL, Kevin Michael 50 Northern Avenue Boston, Massachusetts 02210 / US | 31 /
BANDARAGE, Upul Keerthi 50 Northern Avenue Boston, Massachusetts 02210 / US | [2023/07] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2023/07] | Application number, filing date | 21725849.0 | 02.04.2021 | [2023/07] | WO2021US25614 | Priority number, date | US202063004717P | 03.04.2020 Original published format: US 202063004717 P | [2023/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021203023 | Date: | 07.10.2021 | Language: | EN | [2021/40] | Type: | A1 Application with search report | No.: | EP4132908 | Date: | 15.02.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 07.10.2021 takes the place of the publication of the European patent application. | [2023/07] | Search report(s) | International search report - published on: | EP | 07.10.2021 | Classification | IPC: | C07D209/08, C07D209/18, C07D209/30, C07D401/06, C07D403/04, C07D403/06, C07D405/14, C07D409/04, C07D409/14, C07D413/04, C07D413/06, C07D417/04, C07D417/06, C07D471/04, C07D493/08, A61K31/404, A61K31/35, A61K31/381, A61P1/00, A61P1/14, A61P1/16 | [2023/07] | CPC: |
A61P1/00 (EP,IL);
C07D405/04 (EP,IL,KR,US);
A61K31/404 (KR);
A61K31/4162 (KR);
A61P1/14 (EP,IL);
A61P1/16 (EP,IL,KR);
A61P11/00 (EP,IL,KR);
A61P11/08 (EP,IL);
A61P11/10 (EP,IL);
A61P17/00 (EP,IL);
A61P31/00 (EP,IL);
A61P31/02 (EP,IL);
A61P35/00 (EP,IL);
C07D209/08 (EP,IL);
C07D209/10 (KR);
C07D209/18 (EP,IL,US);
C07D209/20 (EP,IL,KR);
C07D209/30 (EP,IL,KR,US);
C07D401/04 (EP,IL,KR,US);
C07D401/06 (EP,IL);
C07D403/04 (EP,IL,US);
C07D403/06 (EP,IL,US);
C07D403/12 (US);
C07D405/06 (KR,US);
C07D405/14 (EP,IL,KR,US);
C07D409/04 (EP,IL,KR,US);
C07D409/14 (EP,IL,KR,US);
C07D413/04 (EP,IL,US);
C07D413/06 (EP,IL,US);
C07D413/12 (US);
C07D417/04 (EP,IL,US);
C07D417/06 (EP,IL,US);
C07D471/04 (EP,IL,KR,US);
C07D493/08 (EP,IL,US);
C07F9/117 (US);
C07F9/5325 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/07] | Extension states | BA | 31.10.2022 | ME | 31.10.2022 | Validation states | MA | 31.10.2022 | MD | 31.10.2022 | TN | 31.10.2022 | Title | German: | INDOLDERIVATE ALS ALPHA-1-ANTITRYPSINMODULATOREN ZUR BEHANDLUNG VON ALPHA-1-ANTITRYPSINMANGEL (AATD) | [2023/07] | English: | INDOLE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | [2023/07] | French: | DÉRIVÉS D'INDOLE UTILISÉS EN TANT QUE MODULATEURS D'ALPHA-1-ANTITRYPSINE POUR TRAITER UNE DÉFICIENCE EN ALPHA-1-ANTITRYPSINE (AATD) | [2023/07] | Entry into regional phase | 31.10.2022 | National basic fee paid | 31.10.2022 | Designation fee(s) paid | 31.10.2022 | Examination fee paid | Examination procedure | 31.10.2022 | Examination requested [2023/07] | 31.10.2022 | Date on which the examining division has become responsible | 26.05.2023 | Amendment by applicant (claims and/or description) | 25.10.2023 | Despatch of a communication from the examining division (Time limit: M06) | 29.05.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 26.07.2024 | Reply to a communication from the examining division | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 26.07.2024 | Request for further processing filed | 26.07.2024 | Full payment received (date of receipt of payment) Request granted | 06.08.2024 | Decision despatched | Fees paid | Renewal fee | 31.10.2022 | Renewal fee patent year 03 | 29.04.2024 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]WO9637467 (MERCK FROSST CANADA INC [CA], et al) [X] 1-45 * page 93; line 20; example 20; intermediate 2-(1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl)benzoic acid * * page 97; line 33; intermediate methyl 3-[1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl]benzoate * * page 98; line 12; intermediate 3-[1-(4-Bromobenzyl)-5-methoxy-2-methyl-1H-indol-3-yl]benzoic acid * * page 109; line 3; example 64; 5-[1-(4-Bromobenzyl)-5-methoxy-2-methyl- 1H-indol-3-yl]-2-methyl-benzoic acid *; | [X]US2003165712 (LIN TUNG-SHEN [TW], et al) [X] 1-45 * page 5; compound (I-4) *; | [X]WO2009127686 (KAROBIO AB [SE], et al) [X] 1-45 * page 47; line 1; example 33; scheme 30; 1-(4-methoxyphenyl)-2-phenyl-3-benzyl-1H-indole * * page 53; line 9; scheme 37; example 42; intermediate 4-(3-phenyl-1-(4-methoxyphenyl)-1H-indol-2yl)-3,5-dimethylisoxazole *; | [X]US2013167932 (MAEDA KATSUMI [JP], et al) [X] 1-45 * page 17 and page 18; intermediates D5 and D6 *; | [X]US2013319530 (MAEDA KATSUMI [JP], et al) [X] 1-45 * page 20; intermediates A5, A6 and A7 *; | [A]WO2019243841 (UCL BUSINESS LTD [GB]) [A] 1-54* claims 1, 19, 27 *; | [X] - JAFARPOUR FARNAZ ET AL, "A Fast Track to Indoles and Annulated Indoles through ortho - vs ipso- Amination of Aryl Halides", ORGANIC LETTERS ., US, (20191220), vol. 21, no. 24, doi:10.1021/acs.orglett.9b04202, ISSN 1523-7060, pages 10143 - 10148, XP055811010 [X] 1-45 * page 10145; scheme 3; compounds 4a to 4g, 4i, 4j, 4m to 4r, 5f and 4w * * page 10146; scheme 5; compounds I, II and 4n * DOI: http://dx.doi.org/10.1021/acs.orglett.9b04202 | [X] - HE LIN ET AL, "Transition-metal-free synthesis of multisubstitutedN-arylindoles via reaction of arynes and [alpha]-amino ket", TETRAHEDRON, (20191203), vol. 70, no. 14, doi:10.1016/J.TET.2014.02.028, ISSN 0040-4020, pages 2400 - 2405, XP028638160 [X] 1-45 * page 2401; table 2; compounds 4, 8 to 10, 13 and 14 * DOI: http://dx.doi.org/10.1016/j.tet.2014.02.028 | by applicant | - Am J Respir Crit Care Med, (20030000), vol. 168, no. 7, pages 818 - 900 | - OGUSHI et al., J Clin Invest, (19870000), vol. 80, no. 5, pages 1366 - 74 | - TANASH et al., Int J Chron Obstruct Pulm Dis, (20160000), vol. 11, pages 1663 - 9 | - PIITULAINENTANASH, COPD, (20150000), vol. 12, no. 1, pages 36 - 41 | - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 |